These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35190675)

  • 1. Neurotoxicological profile of the hallucinogenic compound 25I-NBOMe.
    Herian M; Wojtas A; Maćkowiak M; Wawrzczak-Bargiela A; Solarz A; Bysiek A; Madej K; Gołembiowska K
    Sci Rep; 2022 Feb; 12(1):2939. PubMed ID: 35190675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe.
    Herian M; Skawski M; Wojtas A; Sobocińska MK; Noworyta K; Gołembiowska K
    Psychopharmacology (Berl); 2021 Aug; 238(8):2349-2364. PubMed ID: 34032876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of serotonin receptor subtypes to hallucinogenic activity of 25I-NBOMe and to its effect on neurotransmission.
    Herian M; Wojtas A; Sobocińska MK; Skawski M; González-Marín A; Gołembiowska K
    Pharmacol Rep; 2020 Dec; 72(6):1593-1603. PubMed ID: 33174181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hallucinogen-Like Action of the Novel Designer Drug 25I-NBOMe and Its Effect on Cortical Neurotransmitters in Rats.
    Herian M; Wojtas A; Kamińska K; Świt P; Wach A; Gołembiowska K
    Neurotox Res; 2019 Jul; 36(1):91-100. PubMed ID: 30989482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOME): A Harmful Hallucinogen Review.
    Kamińska K; Świt P; Malek K
    J Anal Toxicol; 2021 Jan; 44(9):947-956. PubMed ID: 32128596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing.
    Stellpflug SJ; Kealey SE; Hegarty CB; Janis GC
    J Med Toxicol; 2014 Mar; 10(1):45-50. PubMed ID: 23872917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOH.
    Nielsen LM; Holm NB; Leth-Petersen S; Kristensen JL; Olsen L; Linnet K
    Drug Test Anal; 2017 May; 9(5):671-679. PubMed ID: 27400739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective Demonstration of 25I-NBOMe Acute Poisoning Using Hair Analysis.
    Ameline A; Farrugia A; Raul JS; Kintz P
    Curr Pharm Biotechnol; 2017; 18(10):786-790. PubMed ID: 29189143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Locomotor and discriminative stimulus effects of four novel hallucinogens in rodents.
    Gatch MB; Dolan SB; Forster MJ
    Behav Pharmacol; 2017 Aug; 28(5):375-385. PubMed ID: 28537942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats.
    Elmore JS; Decker AM; Sulima A; Rice KC; Partilla JS; Blough BE; Baumann MH
    Neuropharmacology; 2018 Nov; 142():240-250. PubMed ID: 29501528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 25I-NBOMe related death in Australia: a case report.
    Kueppers VB; Cooke CT
    Forensic Sci Int; 2015 Apr; 249():e15-8. PubMed ID: 25747271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 25C-NBOMe and 25I-NBOMe metabolite studies in human hepatocytes, in vivo mouse and human urine with high-resolution mass spectrometry.
    Wohlfarth A; Roman M; Andersson M; Kugelberg FC; Diao X; Carlier J; Eriksson C; Wu X; Konradsson P; Josefsson M; Huestis MA; Kronstrand R
    Drug Test Anal; 2017 May; 9(5):680-698. PubMed ID: 27448631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanosensor for Sensitive Detection of the New Psychedelic Drug 25I-NBOMe.
    Garrido E; Alfonso M; Díaz de Greñu B; Lozano-Torres B; Parra M; Gaviña P; Marcos MD; Martínez-Máñez R; Sancenón F
    Chemistry; 2020 Mar; 26(13):2813-2816. PubMed ID: 31943443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Metabolite Biomarkers of the Designer Hallucinogen 25I-NBOMe in Mouse Hepatic Microsomal Preparations and Human Urine Samples Associated with Clinical Intoxication.
    Poklis JL; Dempsey SK; Liu K; Ritter JK; Wolf C; Zhang S; Poklis A
    J Anal Toxicol; 2015 Oct; 39(8):607-16. PubMed ID: 26378134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response.
    Halberstadt AL; Geyer MA
    Neuropharmacology; 2014 Feb; 77():200-7. PubMed ID: 24012658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MS(n), and LC-HR-MS/MS.
    Caspar AT; Helfer AG; Michely JA; Auwärter V; Brandt SD; Meyer MR; Maurer HH
    Anal Bioanal Chem; 2015 Sep; 407(22):6697-719. PubMed ID: 26108532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 25I-NBOMe, a phenethylamine derivative, induces adverse cardiovascular effects in rodents: possible involvement of p21 (CDC42/RAC)-activated kinase 1.
    Yoon KS; Gu SM; Cha HJ; Kim YH; Yun J; Lee JM
    Drug Chem Toxicol; 2022 Mar; 45(2):898-906. PubMed ID: 32597268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective analysis of the "Neverending Trip" after administration of a potent full agonist of 5-HT2A receptor - 25I-NBOMe.
    Schetz D; Schetz A; Kocić I
    Biomed Pharmacother; 2022 Feb; 146():112295. PubMed ID: 34980551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT
    Eshleman AJ; Wolfrum KM; Reed JF; Kim SO; Johnson RA; Janowsky A
    Biochem Pharmacol; 2018 Dec; 158():27-34. PubMed ID: 30261175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurochemical and Behavioral Profiling in Male and Female Rats of the Psychedelic Agent 25I-NBOMe.
    Miliano C; Marti M; Pintori N; Castelli MP; Tirri M; Arfè R; De Luca MA
    Front Pharmacol; 2019; 10():1406. PubMed ID: 31915427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.